Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis

T. Yanagisawa, T. Kawada, F. Quhal, K. Bekku, E. Laukhtina, P. Rajwa, M. von Deimling, M. Majdoub, M. Chlosta, B. Pradere, K. Mori, T. Kimura, M. Schmidinger, PI. Karakiewicz, SF. Shariat

. 2023 ; 41 (7) : 1763-1774. [pub] 20230520

Jazyk angličtina Země Německo

Typ dokumentu metaanalýza, systematický přehled, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23016991

PURPOSE: To analyze and summarize the efficacy of immune checkpoint inhibitor (ICI) alone or in combination therapy for renal cell carcinoma (RCC) and urothelial carcinoma (UC) stratified by sex. METHODS: Three databases were queried in October 2022 for randomized controlled trials (RCTs) analyzing RCC and UC patients treated with ICIs. We analyzed the association between sex and the efficacy of ICIs in RCC and UC patients across several clinical settings. The outcomes of interest were overall survival (OS) and progression-free survival for the metastatic setting and disease-free survival (DFS) for the adjuvant setting. RESULTS: Overall, 16 RCTs were included for meta-analyses and network meta-analyses. In the first-line treatment of metastatic RCC (mRCC) and UC (mUC) patients, ICI-based combination therapies significantly improved OS compared to the current standard of care, regardless of sex. Adjuvant ICI monotherapy reduced the risk of disease recurrence in female patients with locally advanced RCC (pooled hazard ratio [HR]: 0.71, 95% confidence interval [CI] 0.55-0.93) but not in male patients, and, conversely, in male patients with muscle-invasive UC (pooled HR: 0.80, 95%CI 0.68-0.94) but not in female patients. Treatment ranking analyses in the first-line treatment of mRCC and mUC showed different results between sexes. Of note, regarding adjuvant treatment for RCC, pembrolizumab (99%) had the highest likelihood of improved DFS in males, whereas atezolizumab (84%) in females. CONCLUSIONS: OS benefit of first-line ICI-based combination therapy was seen in mRCC and mUC patients regardless of sex. Sex-based recommendations for ICI-based regimens according to the clinical setting may help guide clinical decision-making.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016991
003      
CZ-PrNML
005      
20231026105345.0
007      
ta
008      
231013s2023 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00345-023-04412-0 $2 doi
035    __
$a (PubMed)37209143
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Yanagisawa, Takafumi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 43 18-20, 1090, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $1 https://orcid.org/0000000274100712
245    10
$a Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis / $c T. Yanagisawa, T. Kawada, F. Quhal, K. Bekku, E. Laukhtina, P. Rajwa, M. von Deimling, M. Majdoub, M. Chlosta, B. Pradere, K. Mori, T. Kimura, M. Schmidinger, PI. Karakiewicz, SF. Shariat
520    9_
$a PURPOSE: To analyze and summarize the efficacy of immune checkpoint inhibitor (ICI) alone or in combination therapy for renal cell carcinoma (RCC) and urothelial carcinoma (UC) stratified by sex. METHODS: Three databases were queried in October 2022 for randomized controlled trials (RCTs) analyzing RCC and UC patients treated with ICIs. We analyzed the association between sex and the efficacy of ICIs in RCC and UC patients across several clinical settings. The outcomes of interest were overall survival (OS) and progression-free survival for the metastatic setting and disease-free survival (DFS) for the adjuvant setting. RESULTS: Overall, 16 RCTs were included for meta-analyses and network meta-analyses. In the first-line treatment of metastatic RCC (mRCC) and UC (mUC) patients, ICI-based combination therapies significantly improved OS compared to the current standard of care, regardless of sex. Adjuvant ICI monotherapy reduced the risk of disease recurrence in female patients with locally advanced RCC (pooled hazard ratio [HR]: 0.71, 95% confidence interval [CI] 0.55-0.93) but not in male patients, and, conversely, in male patients with muscle-invasive UC (pooled HR: 0.80, 95%CI 0.68-0.94) but not in female patients. Treatment ranking analyses in the first-line treatment of mRCC and mUC showed different results between sexes. Of note, regarding adjuvant treatment for RCC, pembrolizumab (99%) had the highest likelihood of improved DFS in males, whereas atezolizumab (84%) in females. CONCLUSIONS: OS benefit of first-line ICI-based combination therapy was seen in mRCC and mUC patients regardless of sex. Sex-based recommendations for ICI-based regimens according to the clinical setting may help guide clinical decision-making.
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    _2
$a inhibitory kontrolních bodů $x terapeutické užití $7 D000082082
650    12
$a karcinom z renálních buněk $x farmakoterapie $7 D002292
650    _2
$a lokální recidiva nádoru $7 D009364
650    12
$a karcinom z přechodných buněk $x farmakoterapie $7 D002295
650    12
$a nádory močového měchýře $7 D001749
650    _2
$a ledviny $7 D007668
650    _2
$a adjuvancia imunologická $7 D000276
650    12
$a nádory ledvin $x farmakoterapie $7 D007680
655    _2
$a metaanalýza $7 D017418
655    _2
$a systematický přehled $7 D000078182
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kawada, Tatsushi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 43 18-20, 1090, Vienna, Austria $u Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan
700    1_
$a Quhal, Fahad $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 43 18-20, 1090, Vienna, Austria $u Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia
700    1_
$a Bekku, Kensuke $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 43 18-20, 1090, Vienna, Austria $u Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan
700    1_
$a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 43 18-20, 1090, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
700    1_
$a Rajwa, Pawel $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 43 18-20, 1090, Vienna, Austria $u Department of Urology, Medical University of Silesia, Zabrze, Poland
700    1_
$a von Deimling, Markus $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 43 18-20, 1090, Vienna, Austria $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Majdoub, Muhammad $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 43 18-20, 1090, Vienna, Austria $u Department of Urology, Hillel Yaffe Medical Center, Hadera, Israel
700    1_
$a Chlosta, Marcin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 43 18-20, 1090, Vienna, Austria $u Clinic of Urology and Urological Oncology, Jagiellonian University, Krakow, Poland
700    1_
$a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 43 18-20, 1090, Vienna, Austria $u Department of Urology, La Croix Du Sud Hospital, Quint Fonsegrives, France
700    1_
$a Mori, Keiichiro $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Kimura, Takahiro $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Schmidinger, Manuela $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 43 18-20, 1090, Vienna, Austria
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 43 18-20, 1090, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at $u Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Weill Cornell Medical College, New York, NY, USA. shahrokh.shariat@meduniwien.ac.at $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at
773    0_
$w MED00004739 $t World journal of urology $x 1433-8726 $g Roč. 41, č. 7 (2023), s. 1763-1774
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37209143 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105340 $b ABA008
999    __
$a ok $b bmc $g 2000485 $s 1203353
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 41 $c 7 $d 1763-1774 $e 20230520 $i 1433-8726 $m World journal of urology $n World J Urol $x MED00004739
LZP    __
$a Pubmed-20231013

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace